Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Cash & Equivalents: 2020-2025

Historic Cash & Equivalents for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Sep 2025 value amounting to $282.0 million.

  • Mirum Pharmaceuticals' Cash & Equivalents rose 26.48% to $282.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $282.0 million, marking a year-over-year increase of 26.48%. This contributed to the annual value of $222.5 million for FY2024, which is 22.29% down from last year.
  • Mirum Pharmaceuticals' Cash & Equivalents amounted to $282.0 million in Q3 2025, which was up 23.63% from $228.1 million recorded in Q2 2025.
  • In the past 5 years, Mirum Pharmaceuticals' Cash & Equivalents registered a high of $303.1 million during Q3 2023, and its lowest value of $49.4 million during Q1 2023.
  • Its 3-year average for Cash & Equivalents is $240.0 million, with a median of $233.2 million in 2024.
  • Per our database at Business Quant, Mirum Pharmaceuticals' Cash & Equivalents slumped by 79.40% in 2023 and then surged by 512.81% in 2024.
  • Quarterly analysis of 5 years shows Mirum Pharmaceuticals' Cash & Equivalents stood at $131.3 million in 2021, then declined by 2.54% to $128.0 million in 2022, then surged by 123.69% to $286.3 million in 2023, then decreased by 22.29% to $222.5 million in 2024, then increased by 26.48% to $282.0 million in 2025.
  • Its last three reported values are $282.0 million in Q3 2025, $228.1 million for Q2 2025, and $211.8 million during Q1 2025.